23 Feb Castle Creek Biosciences

Matthew Gantz, President and CEO

Oct. 14 | 10:30am | BlueRock Therapeutics Ballroom

Exton, PA
(Private)

In-person Presentation
Castle Creek Biosciences is a privately-held, clinical-stage cell and gene therapy company focused on developing and commercializing disease-modifying therapies for patients suffering from rare diseases for which there is a lack of available treatment options. Castle Creek is using its proprietary autologous fibroblast platform to develop dabocemagene autoficel, an investigational, autologous fibroblast cell-based gene therapy that is designed to be administered intradermally to potentially treat the underlying cause of autosomal recessive and dominant dystrophic epidermolysis bullosa. Castle Creek is also developing FCX-013, an investigational, autologous fibroblast cell-based gene therapy that is designed to be administered intradermally to potentially treat moderate to severe localized scleroderma.
www.castlecreekbio.com